SynBAd
/ SagittariusBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 27, 2023
SynBAd, a clinical cancer vaccine candidate, induces antigen-specific T cells and extends life in a therapeutic liver cancer model
(SITC 2023)
- "Conclusions The model used is representative of colon metastases to the liver as well as HBV-driven hepatocellular carcinoma. Localization of the vaccine after administration, activation of antigen specific T cells, mobilization of effector memory T cells, and efficacy in the liver cancer model suggest that this platform promotes a systemic tumor controlling immune response with wide-ranging clinical potential beyond liver cancer."
Clinical • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CD8
1 to 1
Of
1
Go to page
1